A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.
about
A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") miceNeuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's diseaseThe Sex Chromosome Trisomy mouse model of XXY and XYY: metabolism and motor performance.α-Synuclein is a Novel Microtubule Dynamase.Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.β-III Tubulin fragments inhibit α-synuclein accumulation in models of multiple system atrophy.Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein.Protein profiling reveals antioxidant and signaling activities of NAP (Davunetide) in rodent hippocampus exposed to hypobaric hypoxia.A GCase chaperone improves motor function in a mouse model of synucleinopathy.Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits.Olfactory assays for mouse models of neurodegenerative disease.Cognitive deficits in a mouse model of pre-manifest Parkinson's diseaseCritical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy.Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.Parkinson's disease: from genetics to treatments.Intranasal gene delivery for treating Parkinson's disease: overcoming the blood-brain barrier.A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein.Hericium erinaceus mycelium and its isolated erinacine A protection from MPTP-induced neurotoxicity through the ER stress, triggering an apoptosis cascade.Microtubule Destabilization Paves the Way to Parkinson's Disease.Animal models of α-synucleinopathy for Parkinson disease drug development.Alterations in Activity-Dependent Neuroprotective Protein in Sporadic and Experimental Parkinson's Disease.Intranasal Delivery of Recombinant NT4-NAP/AAV Exerts Potential Antidepressant Effect.Impaired baroreflex function in mice overexpressing alpha-synuclein.A viral peptide that targets mitochondria protects against neuronal degeneration in models of Parkinson's disease.Assessment of sensorimotor function in mouse models of Parkinson's disease.Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce α-Synuclein Expression in a Model of Parkinson's Disease.Neuroprotective Effects of Temsirolimus in Animal Models of Parkinson's Disease.NAP (davunetide) protects primary hippocampus culture by modulating expression profile of antioxidant genes during limiting oxygen conditions.Repositioning Microtubule Stabilizing Drugs for Brain Disorders
P2860
Q26859072-29C412CE-52EE-4BFA-8F23-A379C7CF3CDBQ28482356-2E697D25-AE2C-4E03-BD5E-747DF906A1A2Q30417573-CF60DC95-12B9-4876-B5C7-4AB36819505FQ30811315-F2CFE3A5-771D-4F36-8184-17CE48B76DB2Q34056025-A9EE1D89-1D5D-48A9-8F49-0FF78CCC2161Q34107278-B38EFCD0-3216-4511-990D-FC846FCD6766Q34292532-74076C1B-A524-4522-87D2-26D37E2F14DFQ35209222-8A05103C-86E2-43E8-9604-0220F62ED1A9Q35340158-69312CB2-62AA-45D0-84B0-3690C687E3C4Q36787223-56A8ADF3-E19A-4581-ADC3-5118A9AD4C54Q36787949-EE9BCEC9-BFF0-4B4D-A3FA-F8265A241E7AQ37669038-3242B1CC-CFBE-47C1-9F43-30B7ACE1D180Q37986036-1D892A86-4D33-490C-8276-1C627561AE0FQ38022265-7FDFA059-55F0-48C2-8A47-6A896D77A8F1Q38057859-ECF50DD1-B7C8-4DE3-9E93-7B409C656844Q38569775-9A6957A6-18A7-4517-88DF-6552A96D6922Q38741513-189FEC76-E62A-48E6-9F03-5FF9F7B9D862Q38785295-0B4A6342-4759-4E8C-8805-6B8E59065359Q38984991-80E249BB-7D3F-4152-A7D1-D00832CE45B8Q40106906-FC8094BA-CF90-4939-BD3D-6649DE838067Q40838916-852CBA77-5767-4A39-A127-8AF36F3C6EC9Q40929566-6934CED7-1D2D-42D8-A7B0-A51ABE8A822FQ41837152-72F2B11B-EBC7-4646-BF43-D7109A253852Q42183169-45F194AE-7E4E-4598-B661-71CDAAAF2010Q43068412-CADE1B81-2BB3-4F0D-A665-53F81382ADAAQ47130088-140ED907-07A1-4A88-91DC-A375DB146067Q48238673-36DA8042-2C3A-4510-B7C9-A2E2B90F144CQ48303807-16B3EAA5-3A81-4CE1-8CCE-61C81918515FQ58795487-4EF56467-06AD-45FE-9BFF-376B0C58F04E
P2860
A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A pilot trial of the microtubu ...... of alpha-synuclein inclusions.
@ast
A pilot trial of the microtubu ...... of alpha-synuclein inclusions.
@en
A pilot trial of the microtubule-interacting peptide
@nl
type
label
A pilot trial of the microtubu ...... of alpha-synuclein inclusions.
@ast
A pilot trial of the microtubu ...... of alpha-synuclein inclusions.
@en
A pilot trial of the microtubule-interacting peptide
@nl
prefLabel
A pilot trial of the microtubu ...... of alpha-synuclein inclusions.
@ast
A pilot trial of the microtubu ...... of alpha-synuclein inclusions.
@en
A pilot trial of the microtubule-interacting peptide
@nl
P2093
P2860
P1476
A pilot trial of the microtubu ...... of alpha-synuclein inclusions.
@en
P2093
Alistair Stewart
Bruce Morimoto
Caitlin K Mulligan
Carmen Frias
Chunni Zhu
Farzad Mortazavi
Franziska Richter
Illana Gozes
Sheila M Fleming
Vincent Lemesre
P2860
P304
P356
10.1016/J.MCN.2010.12.011
P577
2010-12-27T00:00:00Z